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INTRODUCTION
LIS1 mutations in humans cause a "smooth brain" malformation called lissencephaly (LIS) characterized by severe cognitive and motor impairments and worsening epilepsy, leading to early mortality (Dobyns et al., 1993; Sapir et al., 1999; Gleeson, 2000; Sicca et al., 2003; Saillour et al., 2009; Reiner and Sapir, 2013; Dobyns and Das, 2014; Herbst et al., 2016) . Most of the human mutations result in a null allele with ~50% reduction of LIS1 protein levels, which profoundly impacts the developing nervous system. Other mutations can produce a milder phenotype, but the phenotype/genotype correlation is complex. A classic mouse study made it clear that gene dosage is relevant, as progressive reduction of Lis1 protein levels caused progressively more severe phenotypes (Hirotsune et al., 1998) . Deletion of a large portion of one Lis1 allele in mice, resulting in a null allele, delays neuronal migration and differentiation, but unlike humans, mature mice show mild neurological abnormalities and are viable and fertile (Hirotsune et al., 1998; Gambello et al., 2003) . Cre-mediated knockout (KO) in specific subpopulations of developing neural cells in mice impacts mitosis and nucleokinesis, causing developmental delay (Tsai et al., 2005; Tsai et al., 2007; Yingling et al., 2008; Youn et al., 2009; Hippenmeyer et al., 2010) .
Lis1 is a highly conserved regulator of the minus-end directed microtubule motor protein, cytoplasmic dynein 1; together they regulate neural stem cell spindle orientation, nucleokinesis, and nuclear envelope breakdown during brain development (Vallee et al., 2001; Wynshaw-Boris and Gambello, 2001; Gambello et al., 2003; Shu et al., 2004; Tsai et al., 2005; Vallee and Tsai, 2006; Tsai et al., 2007; Hebbar et al., 2008; Schwamborn and Knoblich, 2008; Yingling et al., 2008; Youn et al., 2009; Hippenmeyer et al., 2010; Moon et al., 2014) . In fact, mutations in the dynein heavy chain gene DYNC1H1 can also cause cortical malformations in humans (Vissers et al., 2010; Willemsen et al., 2012; Poirier et al., 2013) .
Of particular interest are reports that DYNC1H1 mutations cause later onset neurological disorders, including forms of spinal muscular atrophy (SMA) and Charcot-Marie-Tooth Disease (Weedon et al., 2011; Harms et al., 2012) . Additionally, mutations in genes encoding two other dynein regulators DCTN1 and BICD2, cause Perry Syndrome and SMA (Rees et al., 1976; Wider and Wszolek, 2008; Neveling et al., 2013; Oates et al., 2013; Peeters et al., 2013) . The extent to which Lis1 functions post-developmentally, especially in minimally proliferative tissues like adult brain, has not been studied extensively. Baraban et al (2012) found that heterozygous Lis1 KO in 6-week old mice altered synaptic function in the hippocampus in the absence of altered laminar granule cell architecture, but the mechanisms underlying the altered activity are not known (Hunt et al., 2012) . It has been shown that Lis1 manipulations impact dyneindependent axon transport in sensory neurons cultured from adult rats (Smith et al., 2000; Pandey and Smith, 2011) . These results suggest that Lis1 is a positive regulator of dyneinbased axon transport in adult mammals. This was also found in adult mouse DRG neurons (Klinman and Holzbaur, 2015) . Although axon transport studies suggest a role for Lis1 in cultured adult neurons, these neurons do not form synaptic connections, so its involvement in synapse formation and maturation is currently unknown. If Lis1 indeed regulates axon transport in the mature nervous system, Lis1 mutations could have deleterious effects on circuitry in mature brains. We have addressed this fundamental question using a tamoxifen-inducible Cre-Lox system to disrupt Lis1 selectively in adult mice. We show that Lis1 is indispensable in adult mice, and describe unexpected temporal and spatial recombination patterns and how they impact the phenotype of Lis1 KO in adult animals. Our data point to a vital role for Lis1 in cardiorespiratory nuclei in the hindbrain.
MATERIALS AND METHODS
Mice: All animal experiments were conducted under a protocol approved by the Animal Care and Use Committee of the [Author University]. Both males and females were used in experiments, and no differences were observed in outcomes between males and females. Four mouse strains (Jackson Laboratories) were used to generate inducible Lis1 KO mice (Table 1, below). 1) 129S-Pafah1b1 tm2Awb /J (Jackson Laboratory 008002, RRID:IMSR_JAX:008002): loxP sites flank exons 3-6. Homozygous mice are viable and fertile, but have mild hippocampal abnormalities and express ~75% of WT Lis1 levels (Hirotsune et al., 1998) ; 2) Tg(CAG-cre/Esr1*)5Amc/J (Jackson Laboratory 004453, RRID:IMSR_JAX:004453)a chicken β actin promotor drives expression of Cre recombinase fused to a modified estrogen receptor; 3) Tg(Myh6-cre/Esr1*)1Jmk/J (The Jackson Laboratory 005650, RRID:IMSR_JAX:005650) -expression of Cre-ER is under the control of a cardiac-specific αmyosin heavy chain promoter so that tamoxifen stimulates recombination only in cardiac cells; and 4) Gt(ROSA)26Sor tm4(ACTB-tdTomato,-EGFP)Luo /J (The Jackson Laboratory 007576, RRID:IMSR_JAX:007576) -a Cre reporter mouse with loxP sites flanking a membrane-targeted tdTomato cassette that is positioned upstream of a membrane-targeted EGFP cassette. In the reporter mice, cells exhibit membrane-associated red fluorescence until the tdTomato cassette is deleted by Cre recombinase for expression of membrane-associated EGFP fluorescence, thereby allowing visualization of both recombined and non-recombined cells (Muzumdar et al., 2007) . Table 1 shows the crosses that were used to generate experimental animals, and shows the descriptive names used for each throughout the manuscript. All strains used in experiments were homozygous for the Cre reporter. Genotyping of all animals was performed using primers and protocols recommended by Jackson Laboratories. Primers are available on request.
Tamoxifen administration: Tamoxifen was delivered by intraperitoneal (IP) or intracerebroventricular (ICV) injections in adult mice (2-5 months old). For IP delivery, mice were injected with 40 mg/ml tamoxifen (Sigma-Aldrich) dissolved in 10% ethanol and 90% corn oil (Sigma). Two different daily tamoxifen dosage regimens were tested based a previous study using this Lis1 KO strain (Hayashi and McMahon, 2002) : Regimen 1 (5 x 2 mg) -2 mg for five 
DRG cultures:
Cultures were generated from 4-6 month old Lis1 KO and no Cre control mice.
Two methods were used to induce recombination. In some experiments mice were exposed to the 2 x 8 mg tamoxifen IP regimen then neurons harvested on day 4 after the first injection. In other experiments, 4-hydroxytamoxifen (4OHT, 2 µM) was added directly to the DRG cultures with these same genotypes without previous IP injections. Approximately 20 DRGs per mouse were harvested, then dissociated in Type XI collagenase (Sigma) for 1 hour at 37°C, followed by trituration with a flamed Pasteur pipet. Dissociated ganglia were then incubated in 0.05% trypsin (Invitrogen) at 37°C for 15 min. After a second trituration, the cell suspensions were centrifuged through a 12.5% BSA solution to remove myelin fragments and glial cells. Cells were then plated onto sterile, German glass coverslips (Fisher) coated with 10 µg/ml poly-D-lysine (>300 kDa; Sigma) and 10 µg/ml laminin (Millipore). Cells were cultured in DMEM/F12 medium (Corning) with 25mM HEPES, GlutaMAX (Thermo Fisher), N-2 supplement (Life Technologies), and 10% horse serum (HyClone). After 4 days in culture cells were either fixed for analysis of axon length and number of varicosities, or transferred to a live-cell imaging chamber for analysis of organelle transport.
Analysis of axonal varicosities in DRG neurons:
Neurons were cultured for 4 days, and then were fixed in 4% paraformaldehyde. Coverslips were mounted on glass slides using Prolong Gold Antifade (LifeTechnologies). Coverslips were imaged using the ImageXpress XLS (Molecular Devices) high content imaging system equipped with a 20X objective. Axon length and varicosity number were quantified using ImageJ software. The segmented line tool (1 pixel width) was used to trace the axon. Swellings that protruded visibly beyond the 1 pixel line on both sides were counted as varicosities.
Analysis of organelle movement in DRG axons:
Cultures grown on coated glass coverslips were exposed to 100 nM Lysotracker-Red (Millipore Inc.) for 20 min. Coverslips were transferred into fresh medium containing OxyFluor (Oxyrase Inc.) and 25 mM HEPES [pH 7.4], and placed in a custom-built water-heated microscope stage warmed to 37 o C. Organelles were imaged using a Zeiss Axiovert 200 microscope equipped with a C-Apo 63x/1.2 W/0.2 waterimmersion objective. Images were acquired at 0.5 sec intervals for 2 min using a Zeiss AxioCam Quantifying chromatolysis in brainstem sections: Coronal cryosections of mouse brainstem from animals exposed to the 2 x 8 mg tamoxifen regimen were stained with 1% toluidine blue.
The Allen Mouse Brain Atlas was used as a guide to select coronal brainstem sections in which the nucleus ambiguus and other cardiorespiratory centers were likely located. Landmarks such as the fourth ventricle and pyramus granular layers were used to identify the proper sections.
Comparisons were made from matched sections. Substantial Act-Cre-ER mediated recombination (GFP expression) was consistently observed in similar sections following tamoxifen administration. Two hallmarks of chromatolysis were examined -nuclear enlargement and nuclear acentricity. Image J was used to determine nuclear and somal areas and centroids. The ratio of the nuclear area to the somal area was calculated to establish a 'nuclear enlargement index'. A 'centroid displacement index' was calculated by summing the X and Y displacement differences between the nuclear centroid and the somal centroid of each cell.
RNA extraction and analysis: RNA was isolated from flash frozen tissues (see above) using Experimental Design and Statistical Analysis: Mice: were treated with tamoxifen at 2-5 months of age and analysis of tissues was performed when mice showed symptoms of Lis1 KO.
In all, 84 Lis1 KO animals were given the 2 x 8 mg tamoxifen regimen. 100% of these animals began to exhibit neurological symptoms (leg clasping, kyphosis, decreased motility) within a
week. Of these, 18 died during that time, and 66 were euthanized when symptoms became severe. 38 no flLis1 control and 73 no Cre control mice were also given the 2 x 8 mg tamoxifen regimen. None of the controls showed any evidence of neurological disorder or malaise, but most were euthanized at the same time as the Lis1 KO animals to compare results. However 6 each of the control strains were monitored for 4 weeks after 2 x 8 mg tamoxifen and showed no symptoms. We also carried out mock injections of vehicle alone in 12 Lis1 KO animals. These controls also showed no symptoms. 
RESULTS
Lis1 is expressed in adult mouse tissues, prominently in the nervous system. Lis1 protein was found to be expressed in a number of adult mouse tissues. By automated capillary immunoblotting, levels of Lis1 protein were only modestly lower in adult brain than embryonic brain protein samples (Figure 1 ). Substantial Lis1 was also observed in adult spinal cord and dorsal root ganglia. While Lis1 could be detected in adult heart, liver, kidney, lung, and diaphragm, the levels were much lower in all non-nervous tissues tested than in brain, spinal cord and DRG. Therefore, Lis1 may function in other tissues, but is either present in fewer cells or at lower amounts per cell. Figure 2F ). We immunostained these cultures for neurofilament (NF) to label axonal processes specifically so that images could be analyzed using automated software algorithms. However, NF staining was different in the no Cre control and Lis1 KO neurons (Figure 2E, F) . NF was uniformly distributed along axonal processes in no Cre control neurons ( Figure 2E ), while in Lis1 KO neurons NF was more prominent in axon endings, possibly reflecting altered neurofilament transport ( Figure 2F ). Visual inspection and manual measurements in ImageJ showed Lis1 KO neurons had fewer and shorter axons (not shown) and also had significantly more varicosities than the no Cre controls (Mann-Whitney test, p < 0.001 a ; Figure 2G ). Although varicosities occur normally at sites of growth cone pausing or sites of branch formation (Rees et al., 1976; Malkinson and Spira, 2010 ) an increased number is often associated with axonal blockages due to transport defects (Liu et al., 2012) . Indeed, reduced retrograde transport of acidic organelles in living axons was observed in Lis1 KO axons compared to no Cre controls (t-test, p = 3.2 x 10 -32 b ; Figure 2H ) consistent with other studies in adult rat DRG neurons where Lis1 was depleted using siRNA transfections (Pandey and Smith, 2011) .
Knockout (KO) of Lis1 by
Lis1 KO causes a severe phenotype in adult mice. Surprisingly, the 2 x 8 mg regimen caused a rapid decline in health of Lis1 KO animals, with spinal kyphosis ( Figure 3A ) and hind leg clasping ( Figure 3B ) observed 4 days after the first injection. None of the control animals showed this phenotype. In early experiments animals died within a week after the first injection, and mice were subsequently euthanized as soon as they began to exhibit symptoms, typically on days 3-5. Animals that were given a different regimen of tamoxifen, 2 mg injected for 5 consecutive days (5 x 2 mg regimen), remained non-symptomatic for nearly two weeks, after which they exhibited similar symptoms as observed in the 2 x 8 mg regimen. Figure 3C shows symptom-free survival duration plots for these animals. No differences were observed between male and female animals. Most animals were 2 months old at the time of injection, but similar responses were observed in older animals (4-5 months). Control animals did not exhibit any symptoms but were typically euthanized at the same time as KOs to be able to compare tissues for extent of recombination and Lis1 expression levels. However, 6 no Cre control and 6 CAGcre/Esr1 animals that received the 2 x 8 mg tamoxifen regimen lived for over a month with no detectable symptoms ( Figure 3C ).
Temporal differences in tamoxifen-induced recombination in distinct brain regions of
Lis1 KO mice. Lis1 KO mice and no Cre control strains were given the 2 x 8 mg tamoxifen regimen. As expected, the no Cre control brains only exhibited tdTomato fluorescence on day 4 after the first injection ( Figure 4A, left) . In contrast, bright GFP fluorescence was detected in Lis1 KO mice, but surprisingly, primarily in midbrain and hindbrain regions, with little fluorescence detected in the cortices (Figure 4A, right) . A similar result was observed in no flLis1 control so the recombination pattern is similar regardless of whether or not the mice carry the floxed Lis1 alleles.
Although the severity of the phenotype in Lis1 KO mice prevented examination of recombination at later times, no flLis1 control animals Lis1 KO het that remained symptomless for at least 3 weeks after the 2 x 8 mg tamoxifen regimen. These animals showed substantial recombination observed across the entire brain, including the cortex, demonstrating variable rates of recombination in different brain regions with this 2 x 8 mg tamoxifen regimen (shown for Lis1 KO het in Figure 4B ).
In Lis1 KO mice recombination was observed throughout the medulla pons, midbrain and cerebellum and into the spinal cord, but only sparsely in the cortex and hippocampus ( Figure  4C ). At this level of analysis, the most prominent recombination in the cerebellum occurs in the molecular layer in linear profiles reminiscent of Bergmann's glia. Substantial recombination was also observed in the olfactory bulb and choroid plexus ( Figure 4C ). GFP positive cells in the brainstem appeared stellate in shape ( Figure 4D ). White matter tracks in the brainstem and cervical spinal cord were also GFP positive ( Figure 4E ). This GFP distribution correlates with the reduced Lis1 expression observed in brainstem and cerebellum but not in cortex ( Figure 4F ).
Lis1 KO occurs in both neurons and glia.
In cryosections of Lis1 KO DRGs (2 x 8 mg regimen), recombination was observed in both neurons and satellite cells ( Figure 2C ). Figure 5I ) that stained for myelin basic protein ( Figure 5J ). GFP was not observed in the tightly packed myelin sheath itself, so the outer ring likely represents the plasma membrane of the myelinating glial cell. The inner ring was juxtaposed along the axoplasmic membrane of the ensheathed axon, and we interpret this as representing tamoxifen-induced recombination in axons of Lis1 KO neurons. This interpretation is strengthened by the observation that only an outer GFP ring was observed in some myelinated axons ( Figure 5I ), which would be unlikely if the inner GFP-positive ring was also part of the myelinating Schwann cell. Unmyelinated C-fiber bundles in the sciatic nerve are ensheathed by membranes of Schwann cells that do not form myelin. These "Remak bundles" can be observed by EM ( Figure   5K ). Red and green fluorescent rings were often observed in the same Remak bundles indicating that some, but not all axons in the Remak bundle had undergone recombination ( Figure 5L ). Together these data support the in vitro finding that recombination, and by inference, Lis1 KO, occurs in both neurons and glia. The preponderance of recombination in the midbrain, hindbrain, and PNS, coupled with reduction in Lis1 protein levels in these regions, suggest that Lis1 KO in neurons and glia in these regions contributes to the observed neurological phenotypes.
Membrane

Brainstem neurons show chromatolysis in Lis1
KO mice. Figure 6A shows GFP expression in a coronal section through the hindbrain, with a dense concentration of GFP-positive cells in the ventral hindbrain. This area contains nuclei that are vital for cardiorespiratory function, and complete functional loss of these neurons would result in rapid death (Melov et al., 1998; Quintana et al., 2012) . Impairment of axonal transport or other dynein-dependent processes in this region could account for the severe phenotype in Lis1 KO animals. Experimental axotomy and diseases that involve axonal dysfunction can produce the cell body response of chromatolysis (Cragg, 1970; Hanz and Fainzilber, 2006) . Though the mechanisms underlying chromatolysis remain hypothetical, the process is characterized by nuclear swelling and nuclear acentricity, both of which were observed in GFP-rich regions in coronal sections through the brainstem of Lis1 KO ( Figure 6C ). The nuclei were significantly larger and more acentric than controls providing evidence for axonal dysfunction in these neurons (t-test, p = 3.6 x 10 -73 c (D);
Mann-Whitney test, p < 0.0001 d (F); Figure 6D -G).
Lis1 loss in the hindbrain is the most likely cause of the KO phenotype. Lis1 KO mice
receiving the 2 x 8 mg tamoxifen regimen had a much more rapid onset of symptoms compared to the 5 x 2 mg regimen ( Figure 3C) . Indeed, at a time when the 2 x 8 mg mice were severely affected (day 5), the 5 x 2 mg animals had no overt symptoms. Substantially more recombination was observed in the brains of 2 x 8 mg animals compared to 5 x 2 mg animals, which correlates with the onset of severe symptoms ( Figure 7A ) and the level of Lis1 mRNA in the brainstem (one-way ANOVA, F (2, 19) = 5.033, p = 0.0176 g ; Figure 7B ). In contrast, recombination in the heart was similar in both sets of mice ( Figure 7C ), as were Lis1 mRNA levels, which were reduced equally with both regimens (one-way ANOVA, F (2,16) = 19.065, p = 5.83 x 10 -5 h ; Figure 7D ). This indicates that Lis1 KO in the heart is less likely to be responsible for the early onset of symptoms. Other tissues with sporadic GFP (lung, liver, and kidney) also showed a similar degree of recombination with both regimens, supporting the idea that the hindbrain loss of Lis1 contributes significantly to the KO phenotype.
We performed another experiment to directly test contributions of Lis1 KO in the heart to the phenotype observed in Lis1 KO mice by generating an inducible KO in which Cre-ER is driven by a Myh6 promotor (Myh6 KO) (Sohal et al., 2001) . As expected, tamoxifen injections (2 x 8 mg) reduced Lis1 expression in the heart but not in the brainstem of these mice ( Figure 7E ).
Moreover, robust GFP expression, and thus Myh6 KO-dependent recombination, was observed in the heart, but not in the brain (Figure 7F ). Despite significant recombination in the heart, 0/12 mice showed any detectable phenotype, and all lived until apparently symptom free, until euthanized 4 weeks later. Together these data provide evidence that loss of Lis1 in midbrain/hindbrain neurons is responsible for severe phenotype in Lis1 KO mice.
Discussion
In this study we show that Lis1 KO by tamoxifen-induced recombination in Lis1 KO mice causes neuropathology and lethality. Cultured DRG neurons from Lis1 KO animals have axon transport defects and axonal varicosities. Given the preponderance of evidence that Lis1 regulates cytoplasmic dynein, along with the temporal and spatial pattern of recombination and evidence of chromatolysis, the simplest explanation for the severe phenotype is that defective axon transport causes pathological changes in critical subsets of neurons in the brainstem. Lis1
protein is expressed at higher levels in adult brain than in other tissues, and KO specifically in the heart produced no obvious phenotype. However, Lis1 may also play important but undiscovered roles in other tissues.
The finding that Lis1 continues to play a vital role after the majority of mitosis and migration in the brain has occurred supports the idea that Lis1 regulates other dynein-dependent processes like axonal transport. Mouse models in which Lis1 is knocked out developmentally have revealed a much more severe phenotype in homozygotes (preimplantation lethality) relative to heterozygotes (developmental delay in some regions) (Hirotsune et al., 1998) . Our data indicate that this dosage effect is retained in mature animals. Evidence of chromatolysis in brainstem neurons, along with defective morphology and organelle motility in DRG neurons from Lis1 KO mice adds credence to a proposed role for Lis1 in axonal transport and vesicle dynamics in adult mammals.
While our studies unequivocally demonstrate a vital role for Lis1 in adult mice, there are still many unanswered questions. Dynein-based transport also occurs in dendrites, although this has not been studied to the same extent as dynein-based transport in axons (Tear, 2008; Zheng et al., 2008; Kapitein et al., 2010; Wiggins et al., 2012; Arthur et al., 2015; Ayloo et al., 2017) .
Lis1 reportedly impacts retrograde translocation of excitatory synapses in dendrites in hippocampal cultures and organotypic slice cultures from newborn mice (Kawabata et al., 2012) and Lis1 heterozygosity can influence spine morphology in adolescent mice and impacts social behavior (Sudarov et al., 2013) , so it is very likely that postsynaptic processes are also altered in our Lis1 KO mice.
Lis1 is present in Schwann cells in adult DRG cultures, as well as in glial cells in cortical and hippocampal cultures (personal observation). Several reports indicate that Schwann cells and oligodendrocytes also utilize dynein during myelination (Gould et al., 2000; Langworthy and Appel, 2012; Yang et al., 2015) . It is clear from our Lis1 KO reporter studies that glial cells exhibit recombination. If Lis1 contributes to dynein functions in these cells, perturbations in the mouse could affect myelin integrity and dynein-based transport in glial cells, indirectly disrupting neural circuitry. Generating glial and neuronal specific KO animals may allow us to tease apart the contribution of Lis1 to dynein function in different neural cell types.
While tamoxifen induced Lis1 KO in Lis1 KO mice generated a severe and readily observable phenotype, the choice of this Cre-driver complicated the neural specific analysis because other tissues were also targeted for recombination. The severe Lis1 KO phenotype was clearly not due to loss of Lis1 in cardiac muscle, but we cannot completely exclude contributions of Lis1 loss in other tissues. Notably, the recombination in these tissues was highly mosaic at the time when neurological symptoms were severe and euthanasia was performed (not shown). Urine and blood was tested for changes that might signal kidney, bladder, liver or intestine defects, but no significant changes were found (not shown). To try to limit Lis1 loss to the brain we performed stereotaxic injections of 4OHT into lateral ventricles in the Lis1 KO but this resulted in many fewer GFP-positive cells and did not produce a detectable phenotype (not shown). Thus, more selective examination of the role of Lis1 in adult neuronal circuits will require using Credriver(s) specific for different neuronal populations.
An unexpected outcome of our study was the temporal variability in onset of tamoxifen-induced recombination in different brain regions. No Cre control or Lis1 KO het mice remained healthy after the 2 x 8 mg tamoxifen regimen and had very widespread recombination throughout the brain three weeks after the first injection. However, by the time Lis1 KO mice exhibited severe symptoms, recombination was only prominent in the midbrain hindbrain and PNS, so Lis1 loss in the cortex and hippocampus was unlikely to contribute to the KO phenotype. Recombination was observed in axons of the vagus, phrenic and sciatic nerve as well as ventral roots at onset of severe neurological symptoms, adding support to the hypothesis that loss of Lis1 in cardiorespiratory neurons could be a major factor in the Lis1 KO phenotype. The vagus nerve includes autonomic axons emerging or converging on the nucleus ambiguus, solitary nucleus, dorsal nucleus of vagus, and spinal trigeminal nucleus and is involved in cardiorespiratory control. The phrenic nerve contains sympathetic, sensory and motor axons innervating the diaphragm, mediastinal pleura, and pericardium. Sensory and motor neurons with axons in sciatic nerve are less likely to contribute to the death of the animals, but may contribute to leg clasping and kyphosis observed in 100% of Lis1 KO mice.
Brainstem perturbations in animals can lead to death due to cardio-respiratory disruption (Talman and Lin, 2013; Piroli et al., 2016; Sun et al., 2017) . Our data strongly suggests that Lis1 KO in brainstem neurons is a lethal event in mice. Our study raises the question of whether axonal transport is compromised in children with LIS, and if this could contribute to the increasingly frequent and severe seizures and early lethality exhibited by these patients. The brain malformations that occur in utero will not be easy to address in LIS patients. However, axon transport defects might be amenable to treatments after birth with drugs that target the dynein regulatory machinery. Moreover, the symptoms of Perry Syndrome suggest that there is at least respiratory involvement in the disorder (Wider and Wszolek, 2008) . It remains to be determined if less dramatic alterations in the LIS1 gene that might cause more subtle defects in LIS1 expression or function contribute to other types of neurological disorders. There is a growing body of evidence that dynein-related proteins are linked to many neurodegenerative diseases, including SMA, Charcot-Marie-Tooth and Perry Syndrome (Rees et al., 1976; Wider and Wszolek, 2008; Weedon et al., 2011; Harms et al., 2012; Neveling et al., 2013; Oates et al., 2013; Peeters et al., 2013) . Resolving the role of Lis1 in post-developmental neurons and elucidating the pathways regulating axonal transport could uncover new targets for treatment of these neurodegenerative conditions.
In order to treat disorders involving axons transport defects it is critical to elucidate all of the temporal and spatial regulatory mechanisms controlling the transport motors in axons. Many cell culture experiments indicate that Lis1 stimulates dynein processivity (Liu et al., 2000; Smith et al., 2000; Pandey and Smith, 2011; Shao et al., 2013; Klinman and Holzbaur, 2015; Villarin et al., 2016) . However, one transport study indicated that Lis1 knockdown increased mitochondrial transport (Vagnoni et al., 2016) , and several in vitro biophysical studies showed that Lis1 inhibited processivity of purified dynein (Yamada et al., 2008; McKenney et al., 2010; Huang et al., 2012) . More recent assays using purified proteins are beginning to reveal how this might occur at the molecular level in the context of other dynein regulators like dynactin and BICD2 (Baumbach et al., 2017; DeSantis et al., 2017; Gutierrez et al., 2017) . In those studies Lis1 dramatically increased dynein processivity. Interestingly BICD2 mutations that cause SMALED stimulate dynein processivity, so motor activity must be finely tuned (Huynh and Vale, 2017) .
Kinase pathways that impact dynein function have been previously identified. CDK5, mutations in which have been linked to LIS (Magen et al., 2015; Parrini et al., 2016) and CDK1 phosphorylate and regulate the Lis1-and dynein-interacting protein Ndel1 (Hebbar et al., 2008; Pandey and Smith, 2011) . Insulin dependent inhibition of GSK3β, a kinase with a growing list of potential neurological disease links (Dell'Osso et al., 2016) , phosphorylates dynein and regulates its interactions with Ndel1 and APC (Gao et al., 2015; Gao et al., 2017) . It will be interesting to determine if these pathways can be manipulated to alter the severity of the Lis1 KO phenotype, and if they can be used in trying to alleviate symptoms of patients with diseases caused by transport defects. mRNA levels normalized to β2 microglobulin (B2M) mRNA levels from brainstem of no Cre control mice injected with 2 x 8 mg tamoxifen (CON), and Lis1 KO mice injected with either 5 x 2 mg or 2 x 8 mg tamoxifen. Lis1 mRNA levels were significantly decreased in brainstem of 2 x 8 mg animals, but not 5 x 2 mg animals, relative to no Cre controls, 5 days after initial injection. C) Sections of heart from 5 x 2 mg (top) and 2 x 8 mg (bottom) treated Lis1 KO mice.
Figure Legends
Both the 2 x 8 mg and 5 x 2 mg treatment resulted in similar levels of GFP expression in heart. D) Lis1 mRNA levels normalized to B2M mRNA levels from heart of 2 x 8 mg injected no Cre control (CON), 5 x 2 mg, and 2 x 8 mg treated mice. Lis1 mRNA levels were reduced significantly in both the 5 x 2 mg and 2 x 8 mg treated mice relative to the no Cre control, but
were 
